Drugs / TAK-505
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07436728 | May 2026 → Aug 2030 expected | cancer | Takeda | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07436728 ↗ |
| Route | Intravenous | “Participants will receive TAK-505 intravenously (IV)” NCT07436728 ↗ |